A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the JSPR SEC filings page.
This page shows Jasper Therapeutics, Inc. (JSPR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 shows a business where research spending stays elevated as losses deepen and the balance sheet shifts toward liabilities.
R&D increased13.0% in FY2025 while operating cash flow reached-$77.2M , linking heavier investment with continued cash consumption rather than near-term operating relief. The clearest operating signal is the rising resource requirement: R&D reached$63.1M , compared with$51.8M in FY2023, while losses also widened.
The financing structure changed materially: liabilities were
FY2025 financing cash flow was positive at
Financial Health Signals
We do not publish a peer-relative financial health score for Jasper Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Jasper Therapeutics, Inc. passes 0 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Jasper Therapeutics, Inc. reported a net loss of $75.8M while operations used $77.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Jasper Therapeutics, Inc. generated $8.0M in revenue in Q3 2026.
Jasper Therapeutics, Inc.'s EBITDA was -$144.2M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 1322.4%.
Jasper Therapeutics, Inc. reported a net loss of $144.5M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Jasper Therapeutics, Inc. held $135.3M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Jasper Therapeutics, Inc.'s gross margin was 46.0% in Q3 2026, indicating the percentage of revenue retained after direct costs.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q3 2026.
Capital Allocation
Jasper Therapeutics, Inc. invested $8.3M in research and development in Q3 2026. This represents a decrease of 42.1% from the same quarter a year earlier. Against the prior quarter it is up 62.2%.
Not reported for Q3 2026.
Not reported for Q3 2026.
JSPR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | $4.3M-53.8% | $3.6M-77.3% | $3.6M-62.9% | $6.8M | $9.3M+6.4% | $15.8M | $9.8M | N/A |
| Gross Profit | $3.7M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $8.3M-42.1% | $5.1M-75.8% | $5.8M-64.0% | $11.4M-42.5% | $14.4M-0.4% | $21.2M+87.6% | $16.2M+56.9% | $19.8M+42.9% |
| SG&A Expenses | $6.4M+33.2% | $4.1M-30.7% | $5.1M-9.0% | $4.5M-18.8% | $4.8M-12.1% | $5.9M+25.2% | $5.6M+18.2% | $5.5M+41.7% |
| Operating Income | -$144.2Mn/m | -$9.2Mn/m | -$11.0Mn/m | -$15.8Mn/m | -$19.2Mn/m | -$27.1Mn/m | -$21.8Mn/m | -$25.3Mn/m |
| EBITDA | -$144.2Mn/m | $11.8Mn/m | -$10.9Mn/m | -$15.5Mn/m | -$19.0Mn/m | -$26.8Mn/m | -$21.5Mn/m | -$25.0Mn/m |
| Net Income | -$144.5Mn/m | -$2.8Mn/m | -$1.2Mn/m | -$9.1Mn/m | -$18.7Mn/m | -$26.7Mn/m | -$21.2Mn/m | -$24.3Mn/m |
| EPS (Basic) | -$10.19 | -$3.00 | -$1.20 | $6.90 | -$32.08 | -$52.20n/m | -$42.30n/m | -$49.20n/m |
| EPS (Diluted) | -$10.19 | -$3.00 | -$1.20 | $6.90 | -$32.08 | -$52.20n/m | -$42.30n/m | -$49.20n/m |
| Diluted Shares (Avg) | 1M | 956,565 | 955,727 | N/A | 584,056 | 511,132+2.3% | 500,737+12.7% | N/A |
Not reported in any period shown, so not listed: Interest Expense, Income Tax.
JSPR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $147.4M+156.5% | $11.8M-74.6% | $21.2M-63.2% | $35.8M-55.2% | $57.5M-42.2% | $46.5M-59.2% | $57.6M-54.3% | $79.9M-15.8% |
| Current Assets | $147.3M+169.9% | $11.6M-73.1% | $20.3M-61.8% | $34.6M-54.3% | $54.6M-42.4% | $43.0M-60.5% | $53.2M-55.8% | $75.8M-14.8% |
| Cash & Equivalents | $135.3M+165.9% | $7.3M-81.5% | $14.1M-71.0% | $28.7M-59.9% | $50.9M-45.0% | $39.5M-63.0% | $48.8M-58.8% | $71.6M-17.6% |
| Short-Term Investments | N/A | N/A | N/A | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Accounts Receivable | $8.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Investments | N/A | N/A | N/A | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $287.7M+526.7% | $10.4M-54.8% | $17.8M+15.8% | $31.6M+73.5% | $45.9M+191.7% | $23.0M+68.6% | $15.4M+20.6% | $18.2M+10.8% |
| Current Liabilities | $13.9M-33.9% | $7.8M-61.7% | $9.0M-27.1% | $13.2M-13.4% | $21.0M+68.9% | $20.5M+103.6% | $12.3M+38.3% | $15.2M+23.1% |
| Non-Current Liabilities | $273.8M+1001.3% | $2.5M+3.2% | $8.8M+191.1% | $18.4M+516.7% | $24.9M+659.2% | $2.5M-30.6% | $3.0M-20.9% | $3.0M-26.7% |
| Total Equity | -$140.2M-1312.1% | $1.4M-94.0% | $3.4M-92.0% | $4.2M-93.3% | $11.6M-86.2% | $23.5M-76.6% | $42.2M-62.7% | $61.7M-21.4% |
| Retained Earnings | -$465.1Mn/m | -$320.6Mn/m | -$317.8Mn/m | -$316.7Mn/m | -$307.6Mn/m | -$288.8Mn/m | -$262.1Mn/m | -$240.9Mn/m |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
JSPR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.5Mn/m | -$6.9Mn/m | -$14.5Mn/m | -$21.9Mn/m | -$17.0Mn/m | -$15.5Mn/m | -$22.8Mn/m | -$21.1Mn/m |
| Depreciation & Amortization | $16K-92.0% | $21.0M+6900.0% | $21K-92.5% | $290K+18.4% | $200K-60.0% | $300K0.0% | $279K-3.1% | $245K-13.4% |
| Stock-Based Compensation | N/A | N/A | $423K-76.6% | N/A | $1.4M-28.7% | $1.8M+22.6% | $1.8M+54.9% | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | -$17.0M | N/A | N/A | N/A |
| Investing Cash Flow | $7.7Mn/m | N/A | N/A | $0n/m | $0n/m | $1Kn/m | $4Kn/m | -$76Kn/m |
| Financing Cash Flow | $125.8M+343.2% | N/A | N/A | -$340K-198.6% | $28.4M+315322.2% | N/A | N/A | $345Kn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
JSPR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 46.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1802.2% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -1805.7% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -195.3%-81.6pp | -34.5%+15.8pp | -219.3%-179.8pp | -161.9%-139.7pp | -113.7%-99.2pp | -50.3%-38.2pp | -39.4%-18.3pp |
| Return on Assets | -98.0%-65.4pp | -23.4%+34.1pp | -5.5%+31.3pp | -25.4%+5.0pp | -32.6%-13.9pp | -57.5%-44.7pp | -36.9%-26.0pp | -30.4%-13.0pp |
| Current Ratio | 10.59+8.0x | 1.48-0.6x | 2.26-2.1x | 2.62-2.4x | 2.59-5.0x | 2.10-8.7x | 4.31-9.2x | 4.98-2.2x |
| Liabilities-to-Equity | N/A | 7.35+6.4x | 5.23+4.9x | 7.62+7.3x | 3.97+3.8x | 0.98+0.8x | 0.36+0.3x | 0.30+0.1x |
| Asset Turnover | 0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Jasper Therapeutics, Inc. JSPR | FY2025 | N/A | -$75.8M | N/A | $11.9M | — |
| Context Therapeutics Inc. CNTX | FY2025 | N/A | -$36.1M | N/A | $15.5M | — |
| Tvardi Therapeutics, Inc. TVRD | FY2025 | N/A | -$18.2M | N/A | $12.6M | — |
| aTyr Pharma, Inc. ATYR | FY2025 | $190K | -$74.1M | N/A | $9.4M | — |
| Akari Therapeutics plc AKTX | FY2025 | N/A | -$17.3M | N/A | $15.6M | — |
| Citius Pharmaceuticals Inc. CTXR | FY2025 | N/A | -$37.4M | N/A | $13.6M | — |
Where Jasper Therapeutics, Inc. Ranks
Frequently Asked Questions
No, Jasper Therapeutics, Inc. (JSPR) reported a net loss of $157.5M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $75.8M.
Jasper Therapeutics, Inc. (JSPR) had EBITDA of -$82.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Jasper Therapeutics, Inc. (JSPR) has a return on equity of -1826.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Jasper Therapeutics, Inc. (JSPR) recorded an outflow of $77.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Jasper Therapeutics, Inc. (JSPR) had $35.8M in total assets as of fiscal year 2025, including both current and long-term assets.
Jasper Therapeutics, Inc. (JSPR) invested $63.1M in research and development during fiscal year 2025.
Jasper Therapeutics, Inc. (JSPR) had a current ratio of 2.62 as of fiscal year 2025, which is generally considered healthy.
Jasper Therapeutics, Inc. (JSPR) had a liabilities-to-equity ratio of 7.62 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Jasper Therapeutics, Inc. (JSPR) had a return on assets of -211.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Jasper Therapeutics, Inc. (JSPR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $11.9M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Jasper Therapeutics, Inc. (JSPR) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $11.9M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Jasper Therapeutics, Inc. (JSPR) held $28.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $77.2M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Jasper Therapeutics, Inc. (JSPR) has a Piotroski F-Score of 0 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Jasper Therapeutics, Inc. (JSPR) reported a net loss of $75.8M while operations used $77.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.